Ulefnersen met its primary end point in the phase 3 FUSION trial, providing the first placebo-controlled evidence for a genetically targeted therapy in FUS-ALS.
|Slideshows|August 1, 2018
Primary Periodic Paralysis 101
Author(s)Laurie Martin
PPP is a disabling and chronic condition marked by symptoms, such as anxiety, muscle weakness, pain, fatigue, and temporary paralysis.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS
3
ADHERE REAL Study to Assess Real-World Effectiveness of Efgartigimod in CIDP
4
Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab
5